Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Century Therapeutics (IPSC) Assets Average (2022 - 2025)

Historic Assets Average for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $264.7 million.

  • Century Therapeutics' Assets Average fell 3424.01% to $264.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $264.7 million, marking a year-over-year decrease of 3424.01%. This contributed to the annual value of $357.0 million for FY2024, which is 1573.68% down from last year.
  • Century Therapeutics' Assets Average amounted to $264.7 million in Q3 2025, which was down 3424.01% from $300.2 million recorded in Q2 2025.
  • Century Therapeutics' 5-year Assets Average high stood at $541.4 million for Q2 2022, and its period low was $264.7 million during Q3 2025.
  • Over the past 4 years, Century Therapeutics' median Assets Average value was $392.5 million (recorded in 2024), while the average stood at $404.8 million.
  • Its Assets Average has fluctuated over the past 5 years, first plummeted by 118.41% in 2024, then tumbled by 3424.01% in 2025.
  • Quarter analysis of 4 years shows Century Therapeutics' Assets Average stood at $499.1 million in 2022, then decreased by 24.05% to $379.1 million in 2023, then dropped by 2.16% to $370.9 million in 2024, then dropped by 28.64% to $264.7 million in 2025.
  • Its Assets Average was $264.7 million in Q3 2025, compared to $300.2 million in Q2 2025 and $334.4 million in Q1 2025.